Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05666700 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

CAR-T Cell Therapy in RelApsed/Refractory Myeloma With ExtrameduLlary Disease - an in Vivo Imaging and Molecular Monitoring Study

Study acronym: CARAMEL
StatusActive, Not Recruiting
PhasePhase 1
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 11 months later Jan 2026 → Jan 2027
See other at-risk trials from Peter MacCallum Cancer Centre, Australia

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion pushed from Jan 2026 to Jan 2027
    • Enrollment closed, study ongoing
    • Site details revised
    v6
  2. Eligibility criteria expanded, about 2 wordsv5
  3. Enrollment target: 15 to 10
    • Primary completion date: Aug 2025 to Jan 2026
    • Study completion date: Aug 2025 to Jan 2027
    v4
  4. Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Dec 2023 to Dec 8, 2023
    • Site details revised
    v3
  5. Start date: Feb 2023 to Dec 2023v2
  6. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This clinical trial will investigate the in vivo trafficking of cilta-cel in extramedullary myeloma using 64Cu Super Paramagnetic Iron Oxide Nanoparticle (64Cu SPION) and Positron Emission Tomography-Magnetic Resonance Imaging (PET-MRI)
Trial Details
NCT Number NCT05666700
Lead Sponsor Peter MacCallum Cancer Centre, Australia
Collaborators: Janssen, LP
Conditions
(from sponsor)		 Extramedullary Myeloma
Enrollment 10 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov